Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial.

Alireza Ramandi,Jacob George,Shahin Merat,Elham Jafari,Maryam Sharafkhah,Amir Reza Radmard,Alireza Nateghi Baygi,Alireza Delavari,Zahra Mohammadi,Hossein Poustchi,Reza Malekzadeh

Hepatology international（2023）

引用 0|浏览11

暂无评分

摘要

Major cardiovascular events are prevented in MAFLD patients who consume the Polypill. MAFLD patients benefit from the Polypill more than the general population.

查看译文

关键词

Metabolic dysfunction-associated fatty liver disease (MAFLD), Major cardiovascular events, Prevention, Randomized open-labeled trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要